DUBLIN--(BUSINESS WIRE)--The "Global Multiple Sclerosis Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global multiple sclerosis drugs market was valued at US$ 16.13 Billion in 2016, and is expected to reach US$ 27.38 Billion by 2025, expanding at a CAGR of 6.3% from 2017 to 2025.
It is studied that, in the base year 2016, biologics held the largest market share growth mainly driven by Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri. However, it is also estimated that small molecule will be fastest growing segment due to the expected launch of small molecules such as ALKS-8700, OS-440, RPC-1063, ACT-128800 and BAF312.
MS drugs market is segmented on the basis of route of administration such as oral and parenteral route therapeutics. Currently, parenteral MS drugs held the largest market share. The growth of this segment is mainly driven by sales of Avonex, Betaseron, Copaxone, Extavia, Glatopa, Plegridy, Rebif, Zinbryta.
North America held largest MS drugs market share and it is estimated that it will also show fastest growth during forecast period. Rising incidence of MS, technological advances, and higher cost of treatment medication are prime factors that facilitating the growth of MS drugs market in North America.
Key Market Movements:
- Factors such as rising prevalence of multiple sclerosis in some countries and higher treatment compliance are driving the growth of MS drugs market.
- Due to the high unmet needs, vendors in the market are focusing in development of ideal treatment, and promising pipeline molecule. Further increase in incidence of MS would fuel the growth of MS drugs market during forecast period.
-
Unknown etiology of the disease, difficulties in disease diagnosis and
adverse effect of MS medication would negatively impact the growth of
MS drugs market.
Company Profiles
- Abbvie Inc.
- Acorda Therapeutics Inc.
- Bayer HealthCare
- Biogen
- Genzyme (Sanofi)
- GlaxoSmithKline
- Merck Serono
- Novartis
- Pfizer
- Teva
For more information about this report visit https://www.researchandmarkets.com/research/brdlp7/global_27_3?w=4
